Rushad Patell1, Thita Chiasakul1,2, Ethan Bauer3, Jeffrey I Zwicker1. 1. Division of Hemostasis and Thrombosis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States. 2. Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand. 3. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Abstract
BACKGROUND: Coronavirus disease 2019 (COVID-19) increases thrombosis in hospitalized patients prompting adoption of different thromboprophylaxis strategies. Safety and efficacy of escalated-dose pharmacologic thromboprophylaxis are not established. OBJECTIVES: To determine the pooled incidence of thrombosis/bleeding in hospitalized patients with COVID-19 for standard-dose, intermediate-dose, therapeutic anticoagulation, and no pharmacologic thromboprophylaxis. METHODS: MEDLINE, EMBASE, and Cochrane CENTRAL were searched up to August 29, 2020 for studies reporting pharmacologic thromboprophylaxis and thrombosis or bleeding. Pooled event rates were calculated using a random-effects model. RESULTS: Thirty-five observational studies were included. The pooled incidence rates of total venous thromboembolism (N = 4,685) were: no prophylaxis 41.9% (95% confidence interval [CI]: 28.1-57.2, I 2 = 76%), standard-dose prophylaxis 19.8% (95% CI: 13.2-28.6, I 2 = 95%), intermediate-dose prophylaxis 11.9% (95% CI: 4.3-28.6, I 2 = 91%), and therapeutic-dose anticoagulants 10.5% (95% CI: 4.2-23.8, I 2 = 82%, p = 0.003). The pooled incidence rates of arterial thrombosis (N = 1,464) were: no prophylaxis 11.3% (95% CI: 5.2-23.0, I 2 = 0%), standard-dose prophylaxis 2.5% (95% CI: 1.4-4.3, I 2 = 45%), intermediate-dose prophylaxis 2.1% (95% CI: 0.5-7.7, I 2 = 45%), and therapeutic-dose anticoagulants 1.3% (95% CI: 0.2-8.8, I 2 = 0, p = 0.009). The pooled bleeding event rates (N = 6,393) were nonsignificantly higher in therapeutic-dose anticoagulants compared with standard-dose prophylaxis, (6.3 vs. 1.7%, p = 0.083). CONCLUSION: Thrombosis rates were lower in hospitalized COVID-19 patients who received pharmacologic thromboprophylaxis. Thrombosis and bleeding rates for patients receiving intermediate-dose thromboprophylaxis or therapeutic anticoagulation were similar to those who received standard-dose pharmacologic thromboprophylaxis. Thieme. All rights reserved.
BACKGROUND:Coronavirus disease 2019 (COVID-19) increases thrombosis in hospitalized patients prompting adoption of different thromboprophylaxis strategies. Safety and efficacy of escalated-dose pharmacologic thromboprophylaxis are not established. OBJECTIVES: To determine the pooled incidence of thrombosis/bleeding in hospitalized patients with COVID-19 for standard-dose, intermediate-dose, therapeutic anticoagulation, and no pharmacologic thromboprophylaxis. METHODS: MEDLINE, EMBASE, and Cochrane CENTRAL were searched up to August 29, 2020 for studies reporting pharmacologic thromboprophylaxis and thrombosis or bleeding. Pooled event rates were calculated using a random-effects model. RESULTS: Thirty-five observational studies were included. The pooled incidence rates of total venous thromboembolism (N = 4,685) were: no prophylaxis 41.9% (95% confidence interval [CI]: 28.1-57.2, I 2 = 76%), standard-dose prophylaxis 19.8% (95% CI: 13.2-28.6, I 2 = 95%), intermediate-dose prophylaxis 11.9% (95% CI: 4.3-28.6, I 2 = 91%), and therapeutic-dose anticoagulants 10.5% (95% CI: 4.2-23.8, I 2 = 82%, p = 0.003). The pooled incidence rates of arterial thrombosis (N = 1,464) were: no prophylaxis 11.3% (95% CI: 5.2-23.0, I 2 = 0%), standard-dose prophylaxis 2.5% (95% CI: 1.4-4.3, I 2 = 45%), intermediate-dose prophylaxis 2.1% (95% CI: 0.5-7.7, I 2 = 45%), and therapeutic-dose anticoagulants 1.3% (95% CI: 0.2-8.8, I 2 = 0, p = 0.009). The pooled bleeding event rates (N = 6,393) were nonsignificantly higher in therapeutic-dose anticoagulants compared with standard-dose prophylaxis, (6.3 vs. 1.7%, p = 0.083). CONCLUSION:Thrombosis rates were lower in hospitalized COVID-19patients who received pharmacologic thromboprophylaxis. Thrombosis and bleeding rates for patients receiving intermediate-dose thromboprophylaxis or therapeutic anticoagulation were similar to those who received standard-dose pharmacologic thromboprophylaxis. Thieme. All rights reserved.
Authors: Ronald Lg Flumignan; Vinicius T Civile; Jéssica Dantas de Sá Tinôco; Patricia If Pascoal; Libnah L Areias; Charbel F Matar; Britta Tendal; Virginia Fm Trevisani; Álvaro N Atallah; Luis Cu Nakano Journal: Cochrane Database Syst Rev Date: 2022-03-04
Authors: Stefan Kluge; Jakob J Malin; Falk Fichtner; Oliver J Müller; Nicole Skoetz; Christian Karagiannidis Journal: Dtsch Arztebl Int Date: 2021-12-27 Impact factor: 8.251
Authors: Jakob J Malin; Christoph D Spinner; Uwe Janssens; Tobias Welte; Steffen Weber-Carstens; Gereon Schälte; Petra Gastmeier; Florian Langer; Martin Wepler; Michael Westhoff; Michael Pfeifer; Klaus F Rabe; Florian Hoffmann; Bernd W Böttiger; Julia Weinmann-Menke; Alexander Kersten; Peter Berlit; Marcin Krawczyk; Wiebke Nehls; Falk Fichtner; Sven Laudi; Miriam Stegemann; Nicole Skoetz; Monika Nothacker; Gernot Marx; Christian Karagiannidis; Stefan Kluge Journal: Infection Date: 2021-07-06 Impact factor: 3.553
Authors: Patricia Martínez-Botía; Ángel Bernardo; Andrea Acebes-Huerta; Alberto Caro; Blanca Leoz; Daniel Martínez-Carballeira; Carmen Palomo-Antequera; Inmaculada Soto; Laura Gutiérrez Journal: J Clin Med Date: 2021-03-04 Impact factor: 4.241
Authors: Grigoris T Gerotziafas; Mariella Catalano; Yiannis Theodorou; Patrick Van Dreden; Vincent Marechal; Alex C Spyropoulos; Charles Carter; Nusrat Jabeen; Job Harenberg; Ismail Elalamy; Anna Falanga; Jawed Fareed; Petros Agathaggelou; Darko Antic; Pier Luigi Antignani; Manuel Monreal Bosch; Benjamin Brenner; Vladimir Chekhonin; Mary-Paula Colgan; Meletios-Athanasios Dimopoulos; Jim Douketis; Essam Abo Elnazar; Katalin Farkas; Bahare Fazeli; Gerry Fowkes; Yongquan Gu; Joseph Gligorov; Mark A Ligocki; Tishya Indran; Meganathan Kannan; Bulent Kantarcioglu; Abdoul Aziz Kasse; Kostantinos Konstantinidis; Fabio Leivano; Joseph Lewis; Alexander Makatsariya; P Massamba Mbaye; Isabelle Mahé; Irina Panovska-Stavridis; Dan-Mircea Olinic; Chryssa Papageorgiou; Zsolt Pecsvarady; Sergio Pillon; Eduardo Ramacciotti; Hikmat Abdel-Razeq; Michele Sabbah; Mouna Sassi; Gerit Schernthaner; Fakiha Siddiqui; Jin Shiomura; Anny Slama-Schwok; Jean Claude Wautrecht; Alfonso Tafur; Ali Taher; Peter Klein-Wegel; Zenguo Zhai; Tazi Mezalek Zoubida Journal: Thromb Haemost Date: 2021-07-20 Impact factor: 6.681